

Application of the DIVA principle to *Salmonella* Typhimurium vaccines in pigs avoids interference with serosurveillance programmes

Bregje Leyman*

Filip Boyen, Alexander Van Parys, Elin Verbrughe, Freddy Haesebrouck, Frank Pasmans

Ghent University, Faculty of Veterinary Medicine, Department of Pathology, Bacteriology and Avian Diseases

Salisburylaan 133, 9820 Merelbeke, Belgium

* Corresponding author: Tel: +32 9 264 73 76, Fax: +32 9 264 74 94

E-mail address: Bregje.leyman@ugent.be

Abstract

Salmonellosis is one of the most important bacterial zoonotic diseases in humans and *Salmonella* infections are often linked with the consumption of contaminated pork. In order to reduce *Salmonella* Typhimurium infections in humans, minimization of the *Salmonella* intake into the food chain is important. Vaccination has been proposed to control *Salmonella* infections in pigs. However, pigs vaccinated with the current vaccines cannot be discriminated from infected pigs with the lipopolysaccharide (LPS) -based serological tests used in European serosurveillance programmes. We therefore examined which LPS encoding genes of *Salmonella* Typhimurium can be deleted to allow differentiation of infected and vaccinated pigs, without affecting the vaccine strain's protective capacity. For this purpose, deletion mutants in *Salmonella* strain 112910a, used as vaccine strain, were constructed in the LPS encoding genes: *rfbA*, *rfaL*, *rfaJ*, *rfaI*, *rfaG* and *rfaF*. Inoculation of BALB/c mice with the parent strain, *rfaL*, *rfaA* or *rfaJ* strains but not the *rfaG*, *rfaF* or *rfaI* strains protected significantly against subsequent infection with the virulent *Salmonella* Typhimurium strain NCTC12023. Immunization of piglets with the *rfaJ* or *rfaL* mutants resulted in the induction of a serological response lacking detectable antibodies against LPS. This allowed a differentiation between sera from pigs immunized with the *rfaJ* or *rfaL* strains and sera from pigs infected with their isogenic wild type strain.

Introduction

Salmonella infections in humans are often linked with the consumption of contaminated pork [1] [2]. Vaccination has been proposed to control *Salmonella* infections in pigs [1] [3] [4] and has already proven to be efficient in laying hens, reducing faecal shedding and internal egg contamination [5] [6]. Currently, one licensed *Salmonella* Typhimurium live vaccine for pigs is commercially available in Europe [7]. The use of this vaccine is limited due to interference with European *Salmonella* serosurveillance programmes based on the detection of antibodies against the lipopolysaccharides (LPS) of *Salmonella* [8]. It was therefore the aim of this study to develop a DIVA-vaccine strain (Differentiation of Infected and Vaccinated Animals), without attenuating the vaccine strain, which would not interfere with current LPS-ELISA based serosurveillance programmes.

Material and Methods

Salmonella Typhimurium strain 112910a, phage type 120/ad, isolated from a pig stool sample and characterized previously [3], was used as the wild type background to construct several isogenic LPS knock-out mutants: *rfbA*, *rfaL*, *rfaJ*, *rfaI*, *rfaG* and *rfaF*. A commercially available enzyme-linked immunosorbent assay (ELISA) (HerdChek *Salmonella*; IDEXX Laboratories, Schiphol-Rijk, Noord-Holland, The Netherlands) for the detection of porcine antibodies against the LPS of *Salmonella* was used as a reference according to the manufacturer's instructions. Besides, an in-house *Salmonella* Typhimurium strain 112910a whole cell ELISA to detect porcine anti *Salmonella* Typhimurium antibodies, was prepared as described before [9]. In a mouse model, we tested whether the LPS mutants affect the protective capacity of *Salmonella* Typhimurium strain 112910a against a subsequent challenge with a highly virulent strain. For that purpose, seven groups of ten mice were inoculated first via the orogastric route with 2×10^7 CFU/ml of one of the LPS mutant strains (either: *rfbA*, *rfaL*, *rfaJ*, *rfaI*, *rfaG* or *rfaF*) or with the wild type *Salmonella* Typhimurium strain 112910a. Four weeks after primary inoculation, all mice were challenged with 10^8 CFU of the virulent *Salmonella* Typhimurium strain NCTC-12023Nal20 by the orogastric route. In a second in vivo study, we examined whether it was possible to discriminate between the serological response induced after immunization of pigs with either *Salmonella* Typhimurium strain 112910a or one of its isogenic strains (*rfaL* *rfaJ*) on the one hand and after infection of pigs with *Salmonella* Typhimurium strain

112910a on the other hand. Therefore, 14 piglets were randomly allocated to three vaccinated groups (n = 12) and one sham-vaccinated control group (n = 2). Vaccinated animals were intramuscularly immunized (2x) with one of the formalin-inactivated Salmonella strains (either: Salmonella Typhimurium strain 112910a, rfaJ or rfaL) in Freund's incomplete adjuvant. To obtain sera from Salmonella Typhimurium infected piglets, one experimental group (n = 3) was orally inoculated with approximately 2×10^7 CFU of Salmonella Typhimurium strain 112910aNaI20.

Results

Vaccination of mice with rfbA, rfaL and rfaJ but not rfaI, rfaG and rfaF protects mice against a Salmonella Typhimurium infection:

Oral immunization of mice with Salmonella Typhimurium strain 112910a, rfbA, rfaL or rfaJ induced a significant ($P < 0.05$) protection against subsequent challenge with NCTC12023NaI20 in both spleen and liver compared to non immunized control animals. Results are shown in figure 1.




Figure 1: Recovery of Salmonella bacteria from various organs of mice immunized with either Salmonella Typhimurium, one of its isogenic LPS mutants or non immunized control animals and subsequently challenged with Salmonella Typhimurium strain NCTC12023NaI20. The log₁₀ value of the ratio of CFU per gram sample and standard deviations are given. An asterisk refers to a significant difference with the control group ($P < 0.05$).

Pigs, immunized with the rfaL or rfaJ mutant, can be serologically differentiated from Salmonella infected animals: Results showed no significant seroconversion ($P > 0.05$) in animals immunized with inactivated rfaJ or rfaL strains and in sham-vaccinated control animals (non immunized and non infected animals), when using the commercial IDEXX ELISA. Conversely, marked seroconversion occurred in pigs immunized with the inactivated Salmonella Typhimurium strain 112910a. Results also illustrate a clear differentiation between sera from piglets immunized with the rfaJ strain or rfaL strain and sera of pigs infected with their isogenic wild type strain. Anti-Salmonella-antibody titers were detected in the serum of all immunized and infected animals, when using the in-house whole cell ELISA. Results are illustrated in figure 2.




Figure 2: Serological results of pigs immunized with $\Delta rfaL$, $\Delta rfaJ$ or *Salmonella Typhimurium* strain 112910a, control pigs (animals that were not immunized and not infected) and pigs infected with *Salmonella Typhimurium* strain 112910a Nal20. Values are represented as a percentage compared to the wild type vaccinated group. We emphasize that these results are based on a small sample size.

Discussion

DIVA vaccines are a recent advance in vaccinology enabling distinction between an animal that is seropositive to a particular infectious agent because it has been vaccinated, and one that is seropositive because it has been infected with virulent field organisms [10]. Because current *Salmonella* serosurveillance programmes are generally based on detection of antibodies against LPS antigens, we selected six LPS genes that might be suitable markers to develop a LPS based DIVA-vaccine. In a mouse in vivo experiment we showed that the *rfaG* and *rfaF* mutant strains were not able to protect BALB/c mice against a subsequent infection with *Salmonella Typhimurium* NCT12023Nal20 and that the *rfal* strain was only able to significantly reduce bacterial counts in the spleen of mice. Conversely, *rfbA*, *rfaL* and *rfaJ* strains, with less truncated LPS, were able to successfully protect BALB/c mice against a *Salmonella Typhimurium* infection and their protective capacity was not impaired compared to their isogenic wild type strain. These results strongly suggest that a confined truncation of LPS is essential to maintain protection against challenge with the virulent strain *Salmonella Typhimurium* NCTC12023Nal20 in mice. The ultimate goal of this study was to verify whether LPS mutant strains were able to elicit a DIVA humoral immune response in pigs. Our results illustrate that both the *rfal* and the *rfaj* strain gave no seroconversion when using a LPS based ELISA, while a clear-cut seroconversion was observed when using an in-house *Salmonella Typhimurium* strain 112910a whole cell ELISA. Besides, immunization of piglets with the *rfaj* or *rfal* mutants resulted in the induction of a serological response allowing clear differentiation between sera from piglets immunized with the *rfaj* or *rfal* strains and sera of pigs infected with their isogenic wild type strain when using a LPS based ELISA.

Conclusion

In conclusion, applying deletions in the *rfaj* or the *rfal* gene in *Salmonella Typhimurium* strain 112910a allows differentiation of infected and vaccinated pigs in an LPS based ELISA without reducing the strain's protective capacities in mice.

References

1. Boyen F., Haesebrouck F., Maes D., Van Immerseel F., Ducatelle R., Pasmans F., Non-typhoidal *Salmonella* infections in pigs: A closer look at epidemiology, pathogenesis and control., *Vet Microbiol*, 130, 2008, 1-19.
2. Majowicz S.E., Musto J., Scallan E., Angulo F.J., Kirk M., O'Brien S.J., Jones T.F., Fazil A., Hoekstra R.M., The global burden of nontyphoidal *Salmonella* gastroenteritis., *Clin Infect Dis*, 50, 2010, 882-889.
3. Boyen F., Pasmans F., Van Immerseel F., Donne E., Morgan E., Ducatelle R., Haesebrouck F., Porcine in vitro and in vivo models to assess the virulence of *Salmonella enterica* serovar *Typhimurium* for pigs., *Lab Anim*, 2009, 43, 46-52.
4. Denagamage T.N., O'Connor A.M., Sargeant J.M., Raji A., McKean J.D., Efficacy of vaccination to reduce *Salmonella* prevalence in live and slaughtered swine: a systematic review of literature from 1979 to 2007.,

- Foodborne Pathog Dis, 2007, 4, 539-49.
5. Collard J.M., Bertrand S., Dierick K., Godard C., Wildemauwe C., Vermeersch K., Duculot J., Van Immerseel F., Pasmans F., Imberechts H., Quinet C., Drastic decrease of Salmonella Enteritidis isolated from humans in Belgium in 2005, shift in phage types and influence on foodborne outbreaks., *Epidemiol Infect*, 2008, 136, 771-81.
 6. Gantois I., Ducatelle R., Timbermont L., Boyen F., Bohez L., Haesebrouck F., Pasmans F., Van Immerseel F., Oral immunisation of laying hens with the live vaccine strains of TAD Salmonella vac E and TAD Salmonella vac T reduces internal egg contamination with Salmonella Enteritidis., *Vaccine*, 2006, 24, 6250-6255.
 7. Lindner T., Springer S., Selbitz H.J., The use of a Salmonella Typhimurium live vaccine to control Salmonella Typhimurium in fattening pigs in field and effects on serological surveillance., *Safepork 2007 – Verona (Italy)*.
 8. Cortinas Abrahantes J., Bollaerts K., Aerts M., Ogunsanya V., Van der Stede Y., Salmonella serosurveillance: different statistical methods to categorise pig herds based on serological data., *Prev Vet Med*, 2009, 89, 59-66.
 9. Leyman B., Boyen F., Van Parys A., Verbrugge E., Haesebrouck F., Pasmans F., Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs., *Vaccine*, 2011, Epub ahead of print.
 10. Michael J., *Clinical Immunology of the Dog and the Cat*. 2nd ed., Manson publishing: The Veterinary press, 2008.